APLNR Antibody (YA9214)
(Synonyms: AGTRL1, APJ, APLNR, Apelin receptor, Angiotensin receptor-like 1, G-protein coupled receptor APJ, G-protein coupled receptor HG11)Based on 1 Customer Validation
APLNR Antibody (YA9214) is a Mouse-derived and non-conjugated IgG3 monoclonal antibody, targeting to APLNR.
-
Host:
Mouse
-
Isotype:
IgG3
-
Application:
WB, ICC/IF, IF-Tissue, IHC-P
-
Reactivity :
human
-
Formulation:
Supplied in PBS(pH7.4) containing 0.1% gelatin and < 0.1% sodium azide.
-
Conjugation:
Non-conjugated
Applications
| Application |
WB
WB: Western Blot
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
IF-Tissue
IF-Tissue: Immunofluorescence-Tissue
|
IHC(P)
|
|---|---|---|---|---|
| Dilution Ratio | 1:500-1000 | 1:50-500 | 1:50-500 |
Product Details
APLNR Antibody (YA9214) is a Mouse-derived and non-conjugated IgG3 monoclonal antibody, targeting to APLNR.
-
Host Mouse
-
Species Reactivityhuman
-
Calculated Molecular Weight Predicted band size: 42 kDa
OMIM: 600052
A synthesized peptide derived from human APLNR.
Endogenous
Affinity purified
Non-conjugated
Unmodified
IgG3
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS(pH7.4) containing 0.1% gelatin and < 0.1% sodium azide.
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at 2-8°C for 1 year, do not freeze.
-
Shipping
Shipping with blue ice.
Background
-
Function
APLNR is a G protein-coupled receptor for peptide hormones apelin (APLN) and apelin receptor early endogenous ligand (APELA/ELA), that plays a role in the regulation of normal cardiovascular function and fluid homeostasis. When acting as apelin receptor, activates both G(i) protein pathway that inhibits adenylate cyclase activity, and the beta-arrestin pathway that promotes internalization of the receptor. APLNR/APJ also functions as mechanoreceptor that is activated by pathological stimuli in a G protein-independent fashion to induce beta-arrestin signaling, hence eliciting cardiac hypertrophy. However, the presence of apelin ligand blunts cardiac hypertrophic induction from APLNR/APJ on response to pathological stimuli. Plays a key role in early development such as gastrulation, blood vessels formation and heart morphogenesis by acting as a APELA receptor (By similarity). May promote angioblast migration toward the embryonic midline, i.e. the position of the future vessel formation, during vasculogenesis (By similarity). Promotes sinus venosus (SV)-derived endothelial cells migration into the developing heart to promote coronary blood vessel development (By similarity). Also plays a role in various processes in adults such as regulation of blood vessel formation, blood pressure, heart contractility and heart failure[1][2][3][4][5][6].
-
Subcellular Localization
Cell membrane
-
Expression
Tissue_Specificity: Expressed in heart, brain, kidney, stomach, spleen, thymus, lung, ovary, small intestine and colon, adipose tissues and pancreas. Expressed in glial cells, astrocytes and neuronal subpopulations. Expressed in embryonic (ESCs) and induced (iPSCs) pluripotent stem cells. -
Isoforms & Post-Translational Modification
APLNR has an amino acid length of 380, molecular weight is 42660 Da.
-
Subunit
Homodimer; dimerization inhibits APLNR-mediated G protein and beta-arrestin signaling pathways compared to monomeric APLNR
-
SwissProt ID
-
Synonyms
AGTRL1, APJ, APLNR, Apelin receptor, Angiotensin receptor-like 1, G-protein coupled receptor APJ, G-protein coupled receptor HG11
Documentation
[1]. Cayabyab M, et al. Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. J Virol. 2000 Dec;74(24):11972-6. [Content Brief]
[2]. Scimia MC, et al. APJ acts as a dual receptor in cardiac hypertrophy. Nature. 2012 Aug 16;488(7411):394-8. [Content Brief]
[3]. Wang Z, et al. Elabela-apelin receptor signaling pathway is functional in mammalian systems. Sci Rep. 2015 Feb 2;5:8170. [Content Brief]
[4]. Yang P, et al. Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial Hypertension. Circulation. 2017 Mar 21;135(12):1160-1173. [Content Brief]
[5]. Yue Y, et al. Structural insight into apelin receptor-G protein stoichiometry. Nat Struct Mol Biol. 2022 Jul;29(7):688-697. [Content Brief]
[6]. Wang WW, et al. Structure-based design of non-hypertrophic apelin receptor modulator. Cell. 2024 Mar 14;187(6):1460-1475.e20. [Content Brief]